A Verger1,2,3, Ph Metellus4,5, Q Sala1, C Colin5, E Bialecki4, D Taieb1,6, O Chinot5,7, D Figarella-Branger5,8, E Guedj9,10,11,12. 1. Department of Nuclear Medicine, APHM, La Timone Hospital, Marseille, France. 2. Department of Nuclear Medicine & Nancyclotep Imaging Platform, CHRU Nancy, Lorraine University, Nancy, France. 3. IADI, INSERM, UMR 947, Lorraine University, Nancy, France. 4. Department of Neurosurgery, Centre Hospitalier Privé Clairval, Marseille, France. 5. INSERM, UMR 911, Aix-Marseille University, Marseille, France. 6. CERIMED, Aix-Marseille University , Marseille, France. 7. Department of Neuro-Oncology, APHM, La Timone Hospital, Marseille, France. 8. Department of Anatomopathology, APHM, La Timone Hospital, Marseille, France. 9. Department of Nuclear Medicine, APHM, La Timone Hospital, Marseille, France. eric.guedj@ap-hm.fr. 10. CERIMED, Aix-Marseille University , Marseille, France. eric.guedj@ap-hm.fr. 11. Institut de Neurosciences de la Timone, CNRS, UMR 7289, Aix-Marseille University, Marseille, France. eric.guedj@ap-hm.fr. 12. Service Central de Biophysique et Médecine Nucléaire, Hôpital de la Timone, 264 rue Saint Pierre, 13005, Marseille, France. eric.guedj@ap-hm.fr.
Abstract
PURPOSE: The World Health Organization Classification of Tumors of the Central Nervous System has recently been updated by the integration of diagnostic and prognostic molecular parameters, giving pivotal attention to IDH mutation as a favourable factor. Amino acid PET is increasingly used in the management of gliomas, but its prognostic value is a matter of debate. The aim of this study was to assess the relationship between IDH mutation and 18F-FDOPA uptake on PET in newly diagnosed gliomas. METHODS: A total of 43 patients, presenting with diffuse astrocytic and oligodendroglial grade II and III gliomas, reclassified according to the 2016 WHO classification of tumours of the CNS, were retrospectively included. They had all undergone 18F-FDOPA PET at an initial stage before surgery and histological diagnosis. 18F-FDOPA uptake values were compared between patients with and without IDH mutation in terms of maximum standardized uptake value (SUVmax) ratios between tumour and normal contralateral brain (T/N), and between tumour and striatum (T/S). RESULTS: Patients with IDH mutation showed higher 18F-FDOPA T/N SUVmax ratios (1.6 vs. 1.2) and T/S SUVmax ratios (0.9 vs. 0.6) than patients without IDH mutation (p < 0.05). CONCLUSION: This study showed paradoxically higher 18F-FDOPA uptake in diffuse grade II and III gliomas with IDH mutation. Despite evident interest in the management of gliomas, and especially in relation to posttherapy evaluation, our findings raise the question of the prognostic value of 18F-FDOPA uptake on PET uptake in this group of patients. This may be related to differences in amino acid integration, metabolism, or cell differentiation.
PURPOSE: The World Health Organization Classification of Tumors of the Central Nervous System has recently been updated by the integration of diagnostic and prognostic molecular parameters, giving pivotal attention to IDH mutation as a favourable factor. Amino acid PET is increasingly used in the management of gliomas, but its prognostic value is a matter of debate. The aim of this study was to assess the relationship between IDH mutation and 18F-FDOPA uptake on PET in newly diagnosed gliomas. METHODS: A total of 43 patients, presenting with diffuse astrocytic and oligodendroglial grade II and III gliomas, reclassified according to the 2016 WHO classification of tumours of the CNS, were retrospectively included. They had all undergone 18F-FDOPA PET at an initial stage before surgery and histological diagnosis. 18F-FDOPA uptake values were compared between patients with and without IDH mutation in terms of maximum standardized uptake value (SUVmax) ratios between tumour and normal contralateral brain (T/N), and between tumour and striatum (T/S). RESULTS:Patients with IDH mutation showed higher 18F-FDOPA T/N SUVmax ratios (1.6 vs. 1.2) and T/S SUVmax ratios (0.9 vs. 0.6) than patients without IDH mutation (p < 0.05). CONCLUSION: This study showed paradoxically higher 18F-FDOPA uptake in diffuse grade II and III gliomas with IDH mutation. Despite evident interest in the management of gliomas, and especially in relation to posttherapy evaluation, our findings raise the question of the prognostic value of 18F-FDOPA uptake on PET uptake in this group of patients. This may be related to differences in amino acid integration, metabolism, or cell differentiation.
Authors: Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn Journal: Neuro Oncol Date: 2016-04-21 Impact factor: 12.300
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Nathalie L Jansen; Bogdana Suchorska; Vera Wenter; Sabina Eigenbrod; Christine Schmid-Tannwald; Andreas Zwergal; Maximilian Niyazi; Mark Drexler; Peter Bartenstein; Oliver Schnell; Jörg-Christian Tonn; Niklas Thon; Friedrich-Wilhelm Kreth; Christian la Fougère Journal: J Nucl Med Date: 2013-12-30 Impact factor: 10.057
Authors: Zachary J Reitman; Genglin Jin; Edward D Karoly; Ivan Spasojevic; Jian Yang; Kenneth W Kinzler; Yiping He; Darell D Bigner; Bert Vogelstein; Hai Yan Journal: Proc Natl Acad Sci U S A Date: 2011-02-02 Impact factor: 12.779
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: Hiroyuki Tatekawa; Akifumi Hagiwara; Hiroyuki Uetani; Jingwen Yao; Talia C Oughourlian; Shadfar Bahri; Chencai Wang; Catalina Raymond; Albert Lai; Timothy F Cloughesy; Phioanh L Nghiemphu; Linda M Liau; Whitney B Pope; Noriko Salamon; Benjamin M Ellingson Journal: J Neurooncol Date: 2020-09-14 Impact factor: 4.130